{
    "clinical_study": {
        "@rank": "21750", 
        "acronym": "KOGNITO", 
        "arm_group": {
            "arm_group_label": "Kuvan\u00ae", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study is a single-cohort, interventional, open-label trial to evaluate long-term\n      neurocognitive (NC) outcomes in children aged 4 to 5 years with phenylketonuria (PKU)\n      treated with Kuvan\u00ae and Phenylalanine-restricted diet  over a period of 7 years."
        }, 
        "brief_title": "Kuvan\u00ae's Effect on the Cognition of Children With Phenylketonuria", 
        "completion_date": {
            "#text": "April 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Phenylketonuria", 
        "condition_browse": {
            "mesh_term": "Phenylketonurias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female outpatients, 4 to 5 years of age (greater than or equal to 4 and less\n             than 6) at the time of informed consent form signature by parent(s) or guardian(s)\n\n          -  Confirmed clinical and biochemical diagnosis of PKU, including at least two separate\n             blood phenylalanine levels greater than or equal to 400 micromole per liter (mcmol/L)\n\n          -  Defined pre-Kuvan\u00ae/-tetrahydrobiopterin (BH4) dietary phenylalanine tolerance\n             consistent with the diagnosis of PKU\n\n          -  Responsive to Kuvan\u00ae/BH4:\n\n               -  For subjects currently treated with Kuvan\u00ae/BH4 at Screening: subject is a\n                  responder as per Investigator judgment based on documented effect of Kuvan\u00ae/BH4\n                  on phenylalanine levels and/or phenylalanine tolerance\n\n               -  For subjects not treated with Kuvan\u00ae/BH4 at Screening: a response test has been\n                  performed during Screening or is available from the subject's medical records\n                  and satisfies the 3 following criteria: a decrease in blood phenylalanine levels\n                  of at least 30 percent was observed after at least 24 hours with a dose of at\n                  least 10 mg/kg/day\n\n          -  Intelligence Quotient (IQ) greater than or equal to 70, as assessed with the Wechsler\n             Preschool and Primary Scale of Intelligence (WPPSI)-III, 2nd part\n\n          -  Good adherence with dietary treatment (including prescribed dietary phenylalanine\n             restriction and prescribed amounts of phenylalanine-free protein supplements and\n             low-phenylalanine foods), as assessed by the Investigator\n\n          -  Well-controlled phenylalanine levels, as assessed by a minimum of 75 percent of\n             phenylalanine levels within the target recommended in each centre during the previous\n             3 months\n\n          -  Low phenylalanine diet started within the first 3 weeks of life\n\n          -  Parent(s) or guardian(s) willing to comply with all study procedures, maintain strict\n             adherence with the diet, and willing and able to provide written, signed informed\n             consent before any trial-related activities are carried out, as well as ability of\n             child to comply with trial procedures\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to Kuvan\u00ae or its excipients\n\n          -  Known hypersensitivity to other approved or non-approved formulations of BH4\n\n          -  Previous diagnosis of BH4 deficiency\n\n          -  Current use of methotrexate, trimethoprim or other dihydrofolate reductase inhibitors\n\n          -  Current use of medications that are known to affect nitric oxide synthesis,\n             metabolism or action\n\n          -  Current use of experimental or unregistered drugs (other than sapropterin/BH4) that\n             may affect the study outcomes or use of such agents within 30 days prior to Screening\n\n          -  Concurrent use of levodopa\n\n          -  Concurrent disease or condition that would induce repeatedly catabolic situations, or\n             interfere with the trial participation, diet, or NC development, as assessed by the\n             Investigator\n\n          -  Any condition that, in the view of the Investigator, renders the subject at high risk\n             for failure to comply with treatment or to complete the trial\n\n          -  Participation in a clinical trial investigating any other agent than Kuvan\u00ae within\n             the past 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965912", 
            "org_study_id": "EMR 700773-002", 
            "secondary_id": "2009-015844-41"
        }, 
        "intervention": {
            "arm_group_label": "Kuvan\u00ae", 
            "description": "Kuvan\u00ae oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan\u00ae could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).", 
            "intervention_name": "Kuvan\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Sapropterin dihydrochloride"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phenylketonuria", 
            "Kuvan", 
            "Sapropterin dihydrochloride"
        ], 
        "lastchanged_date": "October 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baracaldo Bilbao", 
                        "country": "Spain"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4 Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children With Phenylketonuria Treated With Sapropterin Dihydrochloride (Kuvan\u00ae) for 7 Years", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck KGaA", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: Ethics Committee", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Ethics Committee"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Full Scale Intelligence Quotient (FSIQ) Score of the Wechsler Intelligence Scale for Children (WISC)-IV", 
            "safety_issue": "No", 
            "time_frame": "Year 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965912"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Height compared to the World Health Organization (WHO) Growth Standards", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Weight compared to the World Health Organization (WHO) Growth Standards", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Blood levels of tyrosine, tryptophan, pre-albumin and methylmalonic acid", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Intelligence Quotient (IQ) score and sub-scores such as, verbal IQ, performance IQ, Full Scale Intelligence Quotient (FSIQ) of Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-III", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Intelligence Quotient (IQ) score and sub-scores such as verbal comprehension, perceptual reasoning, working memory, and processing speed indexes and Full Scale Intelligence Quotient (FSIQ) of the Wechsler Intelligence Scale for Children (WISC)-IV", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Change from Baseline in FSIQ score at 2, 4 and 7 years", 
                "safety_issue": "No", 
                "time_frame": "Baseline, and Year 2, 4 and 7"
            }, 
            {
                "measure": "Dietary Phenylalanine tolerance", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Phenylalanine levels", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Index of Dietary Control (IDC)", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Percentage of tablets taken to assess treatment compliance", 
                "safety_issue": "No", 
                "time_frame": "up to 7 years"
            }, 
            {
                "measure": "Distribution of phenylalanine hydroxylase (PAH) genotype", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Number of subjects with Adverse Events and Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 years"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}